OncLive articleshttps://www.onclive.com/newsOncLive articles© 2026 MJH Life Sciences™ and OncLive. All rights reserved.Thu, 08 Oct 2026 19:13:19 +00005en-us14447https://www.onclive.com/newshttps://www.onclive.com/logo.webphttps://www.onclive.com/view/fda-approves-atezolizumab-plus-chemo-for-stage-iii-dmmr-colon-cancerhttps://www.onclive.com/view/fda-approves-atezolizumab-plus-chemo-for-stage-iii-dmmr-colon-cancer<![CDATA[The FDA approved atezolizumab plus chemotherapy for the adjuvant treatment of stage III mismatch repair–deficient colon cancer.]]>Thu, 08 Oct 2026 17:50:49 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/vir-5500-receives-fda-fast-track-designation-in-mcrpchttps://www.onclive.com/view/vir-5500-receives-fda-fast-track-designation-in-mcrpc<![CDATA[The FDA granted fast track designation to the PSMA-targeted T-cell engager VIR-5500 for late-line metastatic castration-resistant prostate cancer.]]>Thu, 08 Oct 2026 17:15:51 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/new-statewide-plan-aims-to-eliminate-cervical-cancer-in-texas-by-2032https://www.onclive.com/view/new-statewide-plan-aims-to-eliminate-cervical-cancer-in-texas-by-2032<![CDATA[MD Anderson Cancer Center announced the Texas Lone Star Cervical Cancer Elimination Plan 2027-2032, a 5-year roadmap to eliminate cervical cancer in Texas.]]>Thu, 08 Oct 2026 16:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/china-s-nmpa-approves-dato-dxd-for-metastatic-tnbc-ineligible-for-pd--l-1-inhibitionhttps://www.onclive.com/view/china-s-nmpa-approves-dato-dxd-for-metastatic-tnbc-ineligible-for-pd--l-1-inhibition<![CDATA[China's approval of Dato-DXd for TNBC was supported by TROPION-Breast02 data showing a median OS of 23.7 months vs 18.7 months with chemotherapy.]]>Thu, 08 Oct 2026 15:57:14 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/iberdomide-plus-daratumumab-dexamethasone-yields-significant-pfs-benefit-in-r-r-myelomahttps://www.onclive.com/view/iberdomide-plus-daratumumab-dexamethasone-yields-significant-pfs-benefit-in-r-r-myeloma<![CDATA[Iberdomide plus daratumumab/dexamethasone improved PFS vs DVd in relapsed/refractory multiple myeloma, meeting a dual primary end point of EXCALIBER-RRMM.]]>Thu, 08 Oct 2026 15:29:12 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/china-s-nmpa-approves-adjuvant-t-dxd-for-her2-early-breast-cancer-with-residual-invasive-diseasehttps://www.onclive.com/view/china-s-nmpa-approves-adjuvant-t-dxd-for-her2-early-breast-cancer-with-residual-invasive-disease<![CDATA[The NMPA approved T-DXd after neoadjuvant therapy, based on DESTINY-Breast05 data, in which the agent lowered the risk of recurrence or death vs T-DM1.]]>Thu, 08 Oct 2026 15:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/breast-cancer-monthly-rewind-key-news-and-expert-insights-you-may-have-missed-in-september-2026https://www.onclive.com/view/breast-cancer-monthly-rewind-key-news-and-expert-insights-you-may-have-missed-in-september-2026<![CDATA[Check out this September recap of OncLive’s coverage of the top news and expert insights in breast cancer.]]>Thu, 08 Oct 2026 13:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/individualized-neoantigen-vaccine-elicits-durable-t-cell-responses-in-resected-hpv-hnscchttps://www.onclive.com/view/individualized-neoantigen-vaccine-elicits-durable-t-cell-responses-in-resected-hpv-hnscc<![CDATA[Adjuvant TG4050 was well tolerated and generated long-lasting neoantigen-specific T-cell responses in resected HPV-negative HNSCC.]]>Thu, 08 Oct 2026 12:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/nonrelapse-mortality-safety-and-long-term-trajectory-after-gvhd-controlhttps://www.onclive.com/view/nonrelapse-mortality-safety-and-long-term-trajectory-after-gvhd-control<![CDATA[Rawan Faramand, MD, says the finding that stands out most from newer approaches is the nonrelapse mortality of about 3% reported in the Precision-T trial, which compares favorably with historical rates of 15% to 20%, particularly in the myeloablative setting.]]>Thu, 08 Oct 2026 12:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/novel-mek-inhibitor-research-aims-to-balance-efficacy-and-tolerability-in-pancreatic-cancerhttps://www.onclive.com/view/novel-mek-inhibitor-research-aims-to-balance-efficacy-and-tolerability-in-pancreatic-cancer<![CDATA[Dr Chung discusses the development of atebimetinib in metastatic pancreatic cancer. ]]>Wed, 07 Oct 2026 22:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/september-roundup-of-fda-approvals-in-oncology-8-decisions-to-knowhttps://www.onclive.com/view/september-roundup-of-fda-approvals-in-oncology-8-decisions-to-know<![CDATA[Here is your cheat sheet to all therapeutic options that were cleared by the FDA in September 2026 spanning tumor types.]]>Wed, 07 Oct 2026 19:47:34 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/fda-approves-tucatinib-plus-trastuzumab-pertuzumab-as-first-line-maintenance-in-advanced-her2-breast-cancerhttps://www.onclive.com/view/fda-approves-tucatinib-plus-trastuzumab-pertuzumab-as-first-line-maintenance-in-advanced-her2-breast-cancer<![CDATA[The FDA approved tucatinib plus trastuzumab and pertuzumab as maintenance for advanced HER2-positive breast cancer after induction.]]>Wed, 07 Oct 2026 17:16:59 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/fda-grants-breakthrough-therapy-designation-to-temab-a-in-previously-treated-c-met-expressing-nonsquamous-nsclchttps://www.onclive.com/view/fda-grants-breakthrough-therapy-designation-to-temab-a-in-previously-treated-c-met-expressing-nonsquamous-nsclc<![CDATA[The c-Met–directed ADC was designated for EGFR wild-type nonsquamous NSCLC after platinum chemotherapy and anti–PD-(L)1 therapy.]]>Wed, 07 Oct 2026 16:25:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/two-dana-farber-researchers-receive-prestigious-new-innovator-award-from-the-national-institutes-of-healthhttps://www.onclive.com/view/two-dana-farber-researchers-receive-prestigious-new-innovator-award-from-the-national-institutes-of-health<![CDATA[Dana-Farber’s Xin Gu, PhD, and Nicholas Polizzi, PhD, received NIH New Innovator Awards for high-risk, high-reward research.]]>Wed, 07 Oct 2026 16:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/fda-grants-breakthrough-therapy-designation-to-telisotuzumab-adizutecan-plus-bevacizumab-in-refractory-mcrchttps://www.onclive.com/view/fda-grants-breakthrough-therapy-designation-to-telisotuzumab-adizutecan-plus-bevacizumab-in-refractory-mcrc<![CDATA[The c-Met–directed ADC-based combination was designated for mCRC previously treated with fluoropyrimidine, irinotecan, oxaliplatin, and anti-VEGF therapy.]]>Wed, 07 Oct 2026 14:55:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/meta-analysis-shows-ropeginterferon-alfa-2b-benefit-over-phlebotomy-but-not-hydroxyurea-inhttps://www.onclive.com/view/meta-analysis-shows-ropeginterferon-alfa-2b-benefit-over-phlebotomy-but-not-hydroxyurea-in<![CDATA[Pooled data from 3 randomized trials showed ropeginterferon alfa-2b improved responses vs phlebotomy alone but not vs hydroxyurea in polycythemia vera.]]>Wed, 07 Oct 2026 13:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/belumosudil-and-the-evolving-role-of-ibrutinib-in-chronic-gvhdhttps://www.onclive.com/view/belumosudil-and-the-evolving-role-of-ibrutinib-in-chronic-gvhd<![CDATA[ROCKSTAR data and real-world experience position belimumab as a convenient, well-tolerated option for steroid-refractory chronic GVHD, while ibrutinib use declines.]]>Wed, 07 Oct 2026 12:05:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/genomic-testing-in-squamous-nsclchttps://www.onclive.com/view/genomic-testing-in-squamous-nsclc<![CDATA[In this segment, the panel discusses the potential role of genomic testing and biomarker identification in advanced squamous non-small cell lung cancer (NSCLC), particularly as new therapeutic approaches emerge following immunotherapy.]]>Wed, 07 Oct 2026 12:05:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/clinical-data-and-practical-considerations-for-bcma-directed-antibody-drug-conjugates-in-relapsed-refractory-multiple-myelomahttps://www.onclive.com/view/clinical-data-and-practical-considerations-for-bcma-directed-antibody-drug-conjugates-in-relapsed-refractory-multiple-myeloma<![CDATA[Dr. Paul Richardson discusses clinical data and practical considerations for belantamab mafodotin as a BCMA-directed antibody-drug conjugate in relapsed/refractory multiple myeloma, highlighting findings from the DREAMM-7 study. ]]>Wed, 07 Oct 2026 12:05:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/emerging-treatment-strategies-in-non-clear-cell-renal-cell-carcinomhttps://www.onclive.com/view/emerging-treatment-strategies-in-non-clear-cell-renal-cell-carcinom<![CDATA[Dr. Voss and Dr. Serzan continue their discussion of treatment strategies for non-clear cell renal cell carcinoma (RCC), focusing on evidence for IO-TKI and IO-IO approaches across different histologic subtypes.]]>Wed, 07 Oct 2026 12:05:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/comparing-sotorasib-and-adagrasib-tolerabilityhttps://www.onclive.com/view/comparing-sotorasib-and-adagrasib-tolerability<![CDATA[Rajwanth R. Veluswamy, MD, MSCR, and Chinmay Jani, MD, of the Perlmutter Cancer Center at NYU Langone Health and the University of Miami Sylvester Comprehensive Cancer Center, compare the tolerability of sotorasib and adagrasib in KRAS G12C-mutated non-small cell lung cancer.]]>Wed, 07 Oct 2026 12:05:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/why-infection-rates-are-similar-across-btk-inhibitorshttps://www.onclive.com/view/why-infection-rates-are-similar-across-btk-inhibitors<![CDATA[Danielle M. Brander, MD, of Duke University School of Medicine, compares infection rates across covalent Bruton tyrosine kinase (BTK) inhibitors in chronic lymphocytic leukemia (CLL).]]>Wed, 07 Oct 2026 12:05:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/long-term-treatment-burden-in-multiple-myelomahttps://www.onclive.com/view/long-term-treatment-burden-in-multiple-myeloma<![CDATA[Jill Burke, NP, and Tanika Pittman, APRN, discuss the operational and patient-related challenges of maintaining long-term therapy for multiple myeloma, with an emphasis on adherence, treatment burden, and preserving quality of life.]]>Wed, 07 Oct 2026 12:05:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/etentamig-iberdomide-and-long-term-perseus-data-headline-key-myeloma-findings-from-ims-2026https://www.onclive.com/view/etentamig-iberdomide-and-long-term-perseus-data-headline-key-myeloma-findings-from-ims-2026<![CDATA[Experts break down key multiple myeloma data and trends from the 23rd Annual IMS Meeting.]]>Wed, 07 Oct 2026 12:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/counseling-patients-on-ruxolitinib-expectations-response-and-the-extended-release-shifthttps://www.onclive.com/view/counseling-patients-on-ruxolitinib-expectations-response-and-the-extended-release-shift<![CDATA[Explore 2026 steroid-refractory chronic GVHD care: four FDA-approved drugs, key trial results, and how ECP fits into real-world treatment selection.]]>Wed, 07 Oct 2026 12:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/durability-and-depth-of-response-with-bcma-directed-bispecific-antibodies-in-relapsed-refractory-multiple-myelomahttps://www.onclive.com/view/durability-and-depth-of-response-with-bcma-directed-bispecific-antibodies-in-relapsed-refractory-multiple-myeloma<![CDATA[Dr. Hans Lee and Dr. Jing Christine Ye discuss the evolution of clinical data for BCMA-directed bispecific antibodies in relapsed/refractory multiple myeloma, focusing on the increasing understanding of response depth and durability with longer follow-up. ]]>Wed, 07 Oct 2026 12:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/ighv-and-tp53-status-in-choosing-fixed-duration-vs-continuous-therapyhttps://www.onclive.com/view/ighv-and-tp53-status-in-choosing-fixed-duration-vs-continuous-therapy<![CDATA[Danielle M. Brander, MD, of Duke University School of Medicine, notes that long-term CLL14 follow-up in chronic lymphocytic leukemia (CLL) showed a median progression-free survival of about 76 months with venetoclax plus obinutuzumab overall but roughly 64 months in unmutated IGHV disease and 49 to 50 months with TP53 aberrations.]]>Wed, 07 Oct 2026 12:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/emerging-kras-g12c-inhibitors-in-developmenthttps://www.onclive.com/view/emerging-kras-g12c-inhibitors-in-development<![CDATA[Rajwanth R. Veluswamy, MD, MSCR, and Chinmay Jani, MD, of the Perlmutter Cancer Center at NYU Langone Health and the University of Miami Sylvester Comprehensive Cancer Center, discuss emerging KRAS G12C-directed agents in development for non-small cell lung cancer.]]>Wed, 07 Oct 2026 12:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/treatment-considerations-in-non-clear-cell-renal-cell-carcinomhttps://www.onclive.com/view/treatment-considerations-in-non-clear-cell-renal-cell-carcinom<![CDATA[Dr. Voss and Dr. Serzan turn to non-clear cell renal cell carcinoma (RCC), highlighting the heterogeneity of these tumors and the ongoing unmet need for more effective treatment strategies.]]>Wed, 07 Oct 2026 12:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/mrd-assessment-in-multiple-myelomahttps://www.onclive.com/view/mrd-assessment-in-multiple-myeloma<![CDATA[Tanika Pittman, APRN, explains how minimal residual disease (MRD) assessment can be used to evaluate treatment response in multiple myeloma, emphasizing the importance of communicating the concept in clear, patient-friendly terms.]]>Wed, 07 Oct 2026 12:00:00 GMTOncLiveusOncLive Articles